ClinicalTrials.gg
Active, not recruitingNCT05388006Updated Oct 5, 2026

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Phase 2 interventional study of Acalabrutinib and Durvalumab in Chronic Lymphocytic Leukemia, Richter Syndrome and Small Lymphocytic Lymphoma, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Updated Oct 5, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
29th of 39
27 · median 61
Started
2023
with 3 others
Phase 2
22 of 39
8 open now
Primary completion
2026-09
later than 10 of 27 live
Registered
29th of 39
by date
Lead sponsor
2 of 39
Mayo Clinic

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 29th largest by planned enrollment, is one of 4 that started in 2023, is one of 22 in phase 2, reaches primary completion later than 10 of the 27 other live ones, and was the 29th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This phase II trial tests whether acalabrutinib, venetoclax, and durvalumab work in treating patients with Richter transformation from chronic lymphocytic leukemia or small lymphocytic lymphoma. Richter transformation is a rare condition in which chronic lymphocytic leukemia or small lymphocytic lymphoma changes into a fast-growing type of lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving acalabrutinib, venetoclax, and durvalumab may help improve survival in patients with Richter transformation.

Read the detailed description

PRIMARY OBJECTIVE:

I. Determine the progression free survival (PFS) at 6 months of the combination therapy of acalabrutinib, venetoclax, and durvalumab in patients with Richter transformation from chronic lymphocytic leukemia (CLL).

SECONDARY OBJECTIVES:

I. Determine the safety of the combination therapy of acalabrutinib, venetoclax and durvalumab in patients with Richter transformation from CLL.

II. Evaluate the overall response rate (ORR), complete response (CR) rate, and partial response (PR) rate of the above combination therapy.

III. Overall survival, PFS, and treatment free survival of this above combination therapy.

CORRELATIVE RESEARCH OBJECTIVES:

I. Determine the biomarkers that predict clinical response of this above combination therapy.

II. Determine the immune profiles of patients while receiving this combination of therapy.

OUTLINE:

Patients receive acalabrutinib orally (PO) twice daily (BID) on days 1-28, durvalumab intravenously (IV) over 1 hour on day 1, and venetoclax PO once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.

MAINTENANCE: Patients receive acalabrutinib PO BID and venetoclax PO QD on days 1-90 of each cycle. Cycles repeat every 90 days for 4 cycles in the absence of disease progression or unacceptable toxicity.

Patients also undergo blood sample collection, bone marrow aspiration and biopsy, and positron emission tomography (PET)/computed tomography (CT) or CT throughout the study.

After completion of study treatment, patients are followed up at 30 days and then every 90 days until 5 years from study enrollment.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Richter Syndrome
  • Small Lymphocytic Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years willing to provide consent and follow-up
  • Diagnosis of CLL according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2018 criteria (Hallek et al., 2018) or small lymphocytic lymphoma (SLL) according to the World Health Organization (WHO) 2008 criteria (Harris, 1999). This includes previous documentation of:

    • -proven SLL according to WHO 2008 criteria, or
    • Diagnosis of CLL according to IWCLL 2018 criteria as evidenced by all of the following:

      • Peripheral blood B cell count of >= 5 x 10\^9/L consisting of small to moderate size lymphocytes (If there are enough evidence to document the prior diagnosis of CLL, it is not required to meet the criteria of peripheral blood B cell count more than 5 x 10\^9/L )
      • Immunophenotyping consistent with CLL defined as:

        • The predominant population of lymphocytes share both B-cell antigens (CD19, CD20 [typically dim expression], or CD23) as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc.)
        • Clonality as evidenced by kappa or lambda light chain expression (typically dim immunoglobulin expression) or other genetic method (e.g. immunoglobulin heavy chain variable [IGHV] analysis)

          • NOTE: Splenomegaly, hepatomegaly, or lymphadenopathy are not required for the diagnosis of CLL
      • Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by demonstrating a negative fluorescence in situ hybridization (FISH) analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy or negative immunohistochemical stains for cyclin D1 on involved tissue biopsy
      • If prior CLL diagnosis was confirmed, or CLL diagnosis was confirmed on bone marrow examination or tissue biopsy, peripheral blood B cell count less than 5 x 10\^9/L is allowed
  • Biopsy proven Richter's transformation of the CLL

    • NOTE: Previously treated patients including CLL therapy can be enrolled. If Richter's transformation (RT) developed from prior untreated CLL and has not received any RT directed therapy, then patient is not eligible
  • Richter patients with prior or concurrent CLL diagnosis and do not have other option for standard therapy per treating physician's discretion
  • can be detected in positron emission tomography (PET) or computed tomography (CT) (>= 1 cm in diameter)
  • (ECOG) performance status (PS) of 0, 1, or 2
  • >= 0.7 x 10\^9/L unless marrow was involved by CLL or RT, then absolute neutrophil count (ANC) >= 0.3 x 10\^9/L (=\< 14 days prior to registration)
  • count >= 40 x 10\^9/L unless marrow was involved by CLL or RT, then platelet >= 30 x 10\^9/L without transfusion =\< 1 week prior to study registration (=\< 14 days prior to registration)
  • (Hgb) >= 8 unless marrow was involved by CLL or RT, then Hgb >= 7 without transfusion =\< 1 week prior to study registration (=\< 14 days prior to registration)
  • Total =\< 1.5 x (ULN) unless due to confirmed Gilbert's disease (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician (=\< 14 days prior to registration)

    • Note: If total bilirubin is > 1.5 x ULN, a direct bilirubin should be performed and must be =\< upper limit of normal
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT]) or alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =\< 2.5 X ULN unless liver are present, in which case it must be =\< 5 x ULN (=\< 14 days prior to registration)
  • Calculated of > 30 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) (=\< 14 days prior to registration)
  • Negative pregnancy test done =\< 7 days prior to registration, for women of only

    • NOTE: The following restrictions apply while the patient is receiving study treatment and for the specified times before and after:

      • Female patient of child-bearing potential

        • Female patients of childbearing potential who are not abstinent and intend to be sexually active with a non sterilized male partner must use at least 1 highly effective method of from the time of screening throughout the total duration of the drug treatment and the drug (180 days after the last dose of study treatment). Non-sterilized male partners of a female patient of childbearing potential must use male condom plus spermicide throughout this period. Cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Female patients should also refrain from breastfeeding throughout this period
      • Male patients with a female partner of childbearing potential

        • Non-sterilized male patients who are not abstinent and intend to be sexually active with a female partner of childbearing potential must use a male condom plus spermicide from the time of screening throughout the total duration of the drug treatment and the drug washout period (180 days after the last dose of study treatment). However, periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Male patients should refrain from sperm donation throughout this period
      • Female partners (of childbearing potential) of male patients must also use a highly effective method of contraception throughout this period
      • Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or
      • Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

        • Women \< 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution
        • Women >= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses > 1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago
      • Highly effective methods of contraception, defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly are described below. Note that some contraception methods are not considered highly effective (e.g. male or female condom with or without spermicide; female cap, diaphragm, or sponge with or without spermicide; non-copper containing intrauterine device; progestogen-only oral hormonal contraceptive pills where inhibition of ovulation is not the primary mode of action [excluding Cerazette/desogestrel which is considered highly effective]; and triphasic combined oral contraceptive pills)
      • Effective methods include:

        • Copper T intrauterine device
        • Levonorgestrel-releasing intrauterine system (e.g., Mirena)
        • Implants: Etonogestrel-releasing implants: e.g. Implanon or Norplant
        • Intravaginal: Ethinylestradiol/etonogestrel-releasing intravaginal devices: e.g. NuvaRing
        • Injection: Medroxyprogesterone injection: e.g. Depo-Provera
        • Combined pill: Normal and low dose combined oral contraceptive pill
        • Patch: Norelgestromin/ethinylestradiol-releasing transdermal system: e.g. Ortho Evra
        • Minipill: Progesterone based oral contraceptive pill using desogestrel: Cerazette is currently the only highly effective progesterone-based
        • Tubal ligation
  • Provide informed written consent
  • Willing to return to enrolling institution for follow-up
  • Willing to provide tissue, blood, and bone marrow samples for mandatory correlative research purposes

Exclusion criteria

Exclusion Criteria:

  • Any of the following uncontrolled intercurrent illness:

    • cardiovascular disease such as:

      • Symptomatic arrhythmias
      • Congestive heart failure
      • Myocardial infarction =\< 3 months prior to registration
      • Any class 3 or 4 cardiac disease as defined by the functional classification
      • Uncontrolled hypertension
      • Unstable angina pectoris

        • Note: Subjects with controlled, asymptomatic atrial fibrillation can enroll on study
    • Serious chronic gastrointestinal conditions associated with diarrhea
    • History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML)
    • History of stroke or intracranial hemorrhage within 6 months before first dose of study drug
    • History of bleeding diathesis (e.g., hemophilia, von Willebrand disease)
    • Active uncontrolled infection (e.g., bacterial, viral or fungal, including subjects with positive cytomegalovirus [CMV] deoxyribonucleic acid [DNA] polymerase chain reaction [PCR]) requiring systemic therapy. NOTE: When the infection is controlled with systemic therapy, patients are permitted for this study
    • Active tuberculosis infection (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis [TB] testing in line with local practice)
    • Known (HIV/acquired immunodeficiency syndrome [AIDS]) infection as further severe with this regimen may occur
    • or C serologic status:

      • Hepatitis B surface antigen and hepatitis B PCR positive will be excluded
      • Hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative, and hepatitis B PCR positive will be excluded
      • These above patients once treated for hepatitis B and became hepatitis B PCR negative, they will be eligible
      • PCR positive will be excluded. Once treated and hepatitis C PCR negative will be eligible
      • NOTE: Once patients with active hepatitis treated with effective therapy and adequate disease control, they will be allowed for participation
  • Any of the following because this study involves an agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown

    • Pregnant women
    • Nursing women
    • Men and women of who are unwilling to employ highly effective method of starting with the screening visit through 180 days after the last dose of trial treatment
  • Treated with other active investigational agents (excluding venetoclax, acalabrutinib. or ibrutinib) =\< 5 half -lives of the previous investigational agents, please consult study chair for the specific investigational agent
  • Prior durvalumab treatment. Note: If patients were treated with other prior PD1 blockade or PDL1 blockade, they will still be eligible
  • Active or recent (=\< 2 months) documented or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]) not being controlled. Exceptions:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 3 years may be included but only after consultation with the study physician
    • Patients with celiac disease controlled by diet alone
  • Evidence of interstitial lung disease or active, non-infectious pneumonitis
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Active central nervous system (CNS) lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells that requires therapy
  • Clinically significant coagulopathy per investigator's assessment (stable anticoagulation except warfarin or other vitamin K antagonist will be allowed)
  • Received an allogenic stem cell transplant within the last 2 years; Or prior history of stem cell transplant with history of (GVHD)
  • Active chronic GVHD requiring treatment
  • Chronically taking a strong inhibitor or inducer and moderate inducer and cannot be switched to an alternative agent at least 4 days prior to trial therapy initiation that in the opinion of investigator/treating physicians precludes utilization of trial therapy
  • Patients taking proton pump inhibitor will be excluded. NOTE: Patient may be switch to an H2 blocker or antiacid
  • History of another primary except for:

    • Malignancy treated with curative intent and with no known active disease >= 5 years before the first dose of study drug and of low potential risk for recurrence
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated carcinoma in situ without evidence of disease
    • Indolent malignancy with expected more than 2 years
  • Current or prior use of immunosuppressive medication =\< 5 half-lives of previous immunosuppressive medication. Note: Immunosuppressive medication is in reference to treatment of autoimmune or inflammatory disorders (e.g., with cyclosporine, tacrolimus, methotrexate, azathioprine) due to the potential suppressive effect on T-cells. Prior treatments administered as CLL- or lymphoma-directed treatment are not considered immunosuppressive medication under this criterion, as clarified below. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical , or local steroid injections (e.g., intra articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed =\< 30 mg/day of prednisone or its equivalent
    • Steroids as premedication for reactions (e.g., CT scan premedication)
    • Receipt of =\< 30 days prior to registration. Note: Patients, if enrolled, should not receive live vaccine whilst receiving investigational product (IP) and up to 30 days after the last dose of IP
    • Received monoclonal antibody therapy for CLL or lymphoma > 7 days prior to registration
    • Received a chimeric antigen receptor T-cell therapy for CLL or lymphoma > 30 days prior to registration
    • Received bi-specific antibody therapy for CLL or lymphoma > 7 days prior to registration
    • Consult with the study chair if other specific medication in question
  • Any radiation therapy =\< 1 week prior to registration
  • Any major surgery =\< 28 days prior to registration (Note: Routine tissue or nodal or small procedures typically heal fast will not be counted as surgery)
  • Body weight =\< 30 kg
  • Life expectancy \< 12 weeks
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Treatment (acalabrutinib, durvalumab, venetoclax)

    Patients receive acalabrutinib PO BID on days 1-28, durvalumab IV over 1 hour on day 1, and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. MAINTENANCE: Patients receive acalabrutinib PO BID and venetoclax PO QD on days 1-90 of each cycle. Cycles repeat every 90 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, bone marrow aspiration and biopsy, and PET/CT or CT throughout the study.

    Drug: Acalabrutinib · Biological: Durvalumab · Drug: Venetoclax · Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Procedure: Positron Emission Tomography (PET) · Procedure: Computed Tomography

Interventions

  • Given PO

    Also known as: ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence

  • BiologicalDurvalumab

    Given IV

    Also known as: Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736

  • Given PO

    Also known as: ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspiration

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy

    Also known as: Biopsy of Bone Marrow

  • ProcedurePositron Emission Tomography (PET)

    Undergo PET/CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, Pet Scan, positron emission tomography scan, PT

  • ProcedureComputed Tomography

    Undergo PET/CT or CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography (CT) scan, CT

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Progression will be defined by Lugano positron emission tomography (PET)-computed tomography (CT) based criteria or chronic lymphocytic leukemia (CLL) criteria. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Ninety-five percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner. If patients are censored prior to 6 months, a Kaplan Meier estimate for progression-free survival at 6 months along with the 95% confidence intervals will be reported.

    Time frame: At 6 months (end of cycle 6). Each cycle is 28 days.

Secondary outcomes

  1. Overall response rate

    Overall response rate (for both Richter transformation \[RT\] and CLL, calculated separately) will be estimated by the total number of patients who achieve a complete metabolic response (CMR)/partial metabolic response (PMR) or complete response (CR)/complete response with incomplete marrow recovery (CRi)/nodular partial response (nPR)/partial remission (PR) divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true overall response rate will be calculated. The PR rate and CR rate will also be estimated.

    Time frame: Up to 1 year

  2. Overall survival

    The distribution of overall survival will be estimated using the method of Kaplan-Meier.

    Time frame: From registration to death due to any cause, assessed up to 5 years

  3. Progression-free survival (PFS)

    The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. PFS estimates will be calculated at 3, 6, 12, and 24 months.

    Time frame: From registration to progression or death due to any cause, assessed up to 2 years

  4. Treatment-free survival

    The distribution of treatment-free survival will be estimated using the method of Kaplan-Meier.

    Time frame: From registration to subsequent treatment or death due to any cause, assessed up to 5 years

  5. Incidence of adverse events

    All eligible patients that have initiated treatment will be considered evaluable for assessing adverse event (AE) rate(s). Platelets and hemoglobin will be graded according to the Grading Scale for Hematologic Adverse Events in CLL Studies. The maximum grade for each type of AE will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the AE(s) to the study treatment will be taken into consideration.

    Time frame: Up to 30 days after last dose of study drug

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Sep 2026, 44 months.

Of 207 non-industry phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's 44 months is below that.

Counting every sponsor, half of 248 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Feb 2027 → Sep 2026 and completion Feb 2027 → Mar 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2022
First posted
May 24, 2022
StartActual
Jan 5, 2023
Primary completionActual
Sep 23, 2026was Feb 2027
CompletionEst.
Mar 30, 2031was Feb 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 5, 2026
Sites
2 sites removed
Show 2 removed
  • Stanford Cancer Institute Palo Alto · Palo Alto, United States
  • Washington University School of Medicine · St Louis, United States
Oct 5, 2026
Primary completion
Feb 22, 2027→Sep 23, 2026 (actual)
Oct 5, 2026
Study completion
Feb 22, 2027→Mar 30, 2031
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Active, not recruiting
    2 sites removed
    Show 2 removed
    • Stanford Cancer Institute Palo Alto · Palo Alto, United States
    • Washington University School of Medicine · St Louis, United States
    Primary completion Feb 22, 2027→Sep 23, 2026 (now actual)
    Study completion Feb 22, 2027→Mar 30, 2031
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05388006
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
May 24, 2022
Start date
Jan 5, 2023
Primary completion
Sep 23, 2026
Completion
Mar 30, 2031 (estimated)
Last update
Oct 5, 2026

Study contacts

Paul J. Hampel, MD
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acalabrutinib · Durvalumab · Venetoclax

Start the discussion